Clinical TrialJun 2, 2026, 08:06 AM
RedHill Biopharma Advances Opaganib for Ebola Outbreak Biodefense
AI Summary
RedHill Biopharma is actively discussing collaborations, including with the WHO's SOLIDARITY CORE clinical trial platform, to advance its investigational oral drug opaganib for Ebola virus disease (EVD). Opaganib, a host-directed SPHK2 inhibitor, has shown a 70.2% mortality reduction in a Phase 3 COVID-19 trial when added to standard care and demonstrated preclinical EVD activity, including inhibition in human macrophages and increased survival in one animal model. The company highlights opaganib's dual mechanism of action against EVD, its oral administration, and ease of storage as crucial for addressing the current Bundibugyo ebolavirus outbreak.
Key Highlights
- RedHill is discussing collaborations for opaganib's clinical advancement for Ebola, including with WHO.
- Opaganib showed 70.2% mortality reduction in severe COVID-19 Phase 3 trial (add-on to remdesivir + corticosteroids).
- Improved median time to viral RNA clearance by ">=4" days in opaganib-treated COVID-19 patients.
- Preclinical studies showed opaganib inhibited EVD in human macrophages and increased survival in one animal model.
- Opaganib demonstrated synergistic effect when combined with remdesivir against EVD.
- Opaganib offers a dual mechanism of action against EVD, targeting SPHK2 inhibition and PI3K/Akt pathway.
- The drug is orally administered, easy to store and distribute, supporting biodefense platforms.
- Opaganib has a demonstrated safety and tolerability profile in over 470 clinical trial participants.
Price Impact
More from RDHL